

<b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>					<b>ATTY. DOCKET NO.</b> <b>MGH-028AUS</b>		<b>APPLICATION NO.</b> <b>10/814,852</b>	
<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>					<b>APPLICANT</b> <b>Maurizio Fava, et al.</b>			
Page 1 of 1					<b>FILING DATE</b> <b>March 31, 2004</b>		<b>GROUP</b> <b>3626</b>	
<b>U.S. PATENT DOCUMENTS</b>								
<b>EXAMINER INITIAL</b>		<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>NAME</b>	<b>CLASS</b>	<b>SUB-CLASS</b>	<b>FILING DATE IF APPROPRIATE*</b>	
							<b>RECEIVED</b>	
							<b>SEP 29 2009</b>	
<b>OFFICE OF PETITIONS</b>								
<b>EXAMINER INITIAL</b>		<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>NAME</b>	<b>CLASS</b>	<b>SUB-CLASS</b>	<b>TRANSLATION</b>	
							<b>YES</b>	<b>NO</b>
<b>OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)</b>								
<b>/E.S./</b>		Brown, Jr.; "The Crossover Experiment for Clinical Trials;" Publication of Stanford University Medical Center, Stanford, CA; Biometrics 36; March 1980; pages 69-79						
/E.S./		Carriere; "Crossover Designs for Clinical Trials;" Statistics in Medicine; Vol. 13; April 1993; pages 1063-1069						
/E.S./		Farlow et al.; "A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer's Disease;" European Neurology; Vol. 4, November 2000; pages 236-241						
/E.S./		Hills et al.; "The Two-Period Cross-Over Clinical Trial;" British Journal of Clinical Pharmacology; July 1979; pages 7-20						
/E.S./		Leber et al.; "Threats to the Validity of Clinical Trials Employing Enrichment Strategies for Sample Selection;" Elsevier Science Inc.; Controlled Clinical Trials; Vol. 19, Issue 2 April 1998; pages 178-187						
/E.S./		Raskind et al; "Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension;" American Academy of Neurology; June 2000; pages 2260-2269						
/E.S./		Rosner et al; "Randomized Discontinuation Design: Applied to Cytostatic Antineoplastic Agents;" Journal of Clinical Oncology; Vol. 20, No. 22; November 15, 2002; pages 4478-4484						
/E.S./		Temple; "Special Study Designs: Early Escape, Enrichment, Studies in Non-Responders;" Communications in Statistics-Theory and Method; Vol. 23, Issue 2; 1994; pages 499-531						
<b>Examiner</b>		<b>/Eliza Squires/</b> <b>Date Considered:</b> <b>10/07/2009</b>						
<b>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and considered. Include copy of this form with next communication to applicant.</b>								